Ki-Cheong Park (Ki Cheong Park)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 17

Top Topics

Acinetobacter Baumannii

Papillary Thyroid

Lymph Node Metastasis

Top Venues

International journal of molecular sciences

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Ki-Cheong Park, Jung Min Kim, Sang Yong Kim, Seok-Mo Kim, Jin Hong Lim, Min Ki Kim, Sungsoon Fang, Yonjung Kim, Gordon B Mills, Sung Hoon Noh, Jae-Ho Cheong
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC medicine 21 (1) (2023)
Ki-Cheong Park, Jung Min Kim, Sang Yong Kim, Seok-Mo Kim, Jin Hong Lim, Min Ki Kim, Sungsoon Fang, Yonjung Kim, Gordon B Mills, Sung Hoon Noh, Jae-Ho Cheong
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC medicine 21 (1) (2023)
Ki-Cheong Park, Jung Min Kim, Sang Yong Kim, Seok-Mo Kim, Jin Hong Lim, Min Ki Kim, Sungsoon Fang, Yonjung Kim, Gordon B Mills, Sung Hoon Noh, Jae-Ho Cheong
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC medicine 21 (1) (2023)
Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki-Cheong Park
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma. International journal of molecular sciences 24 (8) (2023)
Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki-Cheong Park
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma. International journal of molecular sciences 24 (8) (2023)
Yuna Kim, Hyeok Jun Yun, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Seok-Mo Kim, Ki-Cheong Park
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer. International journal of molecular sciences 24 (22) (2023)
Ki-Cheong Park, Jung Min Kim, Sang Yong Kim, Seok-Mo Kim, Jin Hong Lim, Min Ki Kim, Sungsoon Fang, Yonjung Kim, Gordon B Mills, Sung Hoon Noh, Jae-Ho Cheong
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC medicine 21 (1) (2023)
Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki-Cheong Park
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma. International journal of molecular sciences 24 (8) (2023)
Hyun Woo Ma, Jung Min Kim, Da Hye Kim, I Seul Park, Ji Hyung Kim, Ki-Cheong Park, Dong Hyuk Seo, Jae Hyeon Kim, Xiumei Che, Tae Il Kim, Jae Hee Cheon, Seung Won Kim
Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer. Cancer gene therapy (2022)
Hyun Woo Ma, Jung Min Kim, Da Hye Kim, I Seul Park, Ji Hyung Kim, Ki-Cheong Park, Dong Hyuk Seo, Jae Hyeon Kim, Xiumei Che, Tae Il Kim, Jae Hee Cheon, Seung Won Kim
Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer. Cancer gene therapy (2022)
Seok-Mo Kim, Keunwan Park, Jin-Hong Lim, Hyeok Jun Yun, Sang Yong Kim, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Cheol-Ho Pan, Ki-Cheong Park
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma. International journal of molecular sciences 23 (18) (2022)
Jin-Hong Lim, Keunwan Park, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Cheol-Ho Pan, Seok-Mo Kim, Ki-Cheong Park
Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. International journal of molecular sciences 23 (14) (2022)
Hyeok Jun Yun, Jin-Hong Lim, Sang-Yong Kim, Seok-Mo Kim, Ki-Cheong Park
Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model. Biomedicines 10 (8) (2022)
Hyeok Jun Yun, Minki Kim, Sang Yong Kim, SungSoon Fang, Yonjung Kim, Hang-Seok Chang, Ho-Jin Chang, Ki-Cheong Park
Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer. International journal of molecular sciences 23 (2) (2022)
Hyeok Jun Yun, Hee Jun Kim, Jungmin Kim, Sang Yong Kim, Hang-Seok Chang, Cheong Soo Park, Ho-Jin Chang, Ki-Cheong Park
Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models. International journal of molecular sciences 22 (2) (2021)
Jin Hong Lim, Kyung Hwa Choi, Soo Young Kim, Cheong Soo Park, Seok-Mo Kim, Ki-Cheong Park
Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. International journal of molecular sciences 21 (20) (2020)
Seok-Mo Kim, Soo Young Kim, Cheong Soo Park, Hang-Seok Chang, Ki-Cheong Park
Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer. Cancers 12 (2) (2020)